“The result is a patent pending, molecular diagnostic platform that will provide greater accuracy and rapid gene quantification at a deeper threshold than any existing molecular device on the market,” Lavance Northington, CEO, Cellgen Diagnostics.
Irvine, California (PRWEB) July 09, 2014
Cellgen Diagnostics announced today the availability of a free whitepaper on a molecular diagnostics platform that can rapidly detect genetic material to identify various illnesses and diseases in humans. It also provides absolute quantification for the purpose of gene expression analysis for research and discovery. Gene Expression analysis helps researchers understand disease pathways, which in turn helps them to identify means to interfere with those disease pathways (e.g. pharmacological) to develop treatments.
Although qPCR (Polymerase Chain Reaction) is the “Gold Standard” for today’s $3B gene expression analysis industry, research professionals have long desired a departmentally affordable, gene expression analysis platform that provides near real-time turnaround times, quantitative digital outputs and automation to remove the currently extensive labor required to perform each test.
The whitepaper, Oil-Encapsulated Nanodroplet Array for Bio-molecular Detection, is available for download at http://cellgendx.com/bmes.html.
In this publication, Cellgen Scientists along with collaborators from the University of California, San Diego describe an ultra-sensitive, on-chip sample concentrating-detection technology for the purpose of biomolecular quantification. This technology is the foundation of Cellgen's proprietary platform that has demonstrated the ability to enrich and concentrate DNA samples up to a million times to allow for low-abundance (femto-molar range) detection of targeted analytes without biochemical amplification within 30 minutes.
“The result is a patent pending, molecular diagnostic platform that will provide greater accuracy and rapid gene quantification at a deeper threshold than any existing molecular device on the market,” said Lavance Northington, CEO of Cellgen Diagnostics.
Blood and biofluids contain many biomolecules, namely proteins, DNAs, and RNAs that can be used as diagnostic biomarkers, but their low concentration levels often make accurate and rapid detection challenging.
“Cellgen’s technology would allow us to look at genetic material - the basis of all illness and disease - and make diagnoses in near real time that, right now, are not possible at the bedside,” said Dr. Alexander Khalessi, Director of Endovascular Neurosurgery at the University of California, San Diego Medical Center. “More importantly, we would be able to tailor our treatment to a specific genetic profile. For me as a clinician, this is going to make the real difference going forward and change the way medicine is practiced.”
Specifically, the technology does not require the thermal cycling component, costly enzymes, or sequence specific labeling procedure like PCR/Amplification technologies, and presents as an innovative solution to provide near real time, quantitative results in a number of markets. These include disease diagnosis, veterinary diagnostics, companion diagnostics, food and safety testing, agriculture improvements, environmental testing, GMO testing and biological research testing.
“Beyond providing health care providers with tools to better attain personalized medicine, our technology will have an immediate impact on the $3B gene expression analysis market. We are highly anticipating the release of our prototype to the biological research markets in Q2/Q3 of 2015,” said Northington.
Faster analysis time, automation and affordability will be the key drivers in the adoption of Cellgen technology in the research and discovery industry.
About Cellgen Diagnostics
Cellgen Diagnostics is developing a highly sensitive and accurate molecular diagnostic platform to provide gene expression analysis for research and discovery and for the detection of Infectious Pathogens in blood and other biological fluids. Based in Irvine, California with R&D facilities located on the campus of University of California, San Diego (UCSD), Cellgen's core platform is based on a portfolio of patent pending technologies exclusively licensed from UCSD.
Designed as an open platform able to detect any and all nucleic acid signatures, this detection platform will offer one of the fastest and most sensitive methods available, detecting concentrations as low 10fM. This level of sensitivity enables the detection of nucleic acids in less than 30 minutes, as compared to 8 hours and in some cases days with conventional methods.
For more information, please visit cellgendx.com.